Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$63 Mln
P/E Ratio
--
P/B Ratio
0.61
Industry P/E
--
Debt to Equity
0
ROE
-0.52 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.67
CFO
$-214.45 Mln
EBITDA
$-262.28 Mln
Net Profit
$-249.40 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Achilles Therapeutics PLC ADR (ACHL)
| 29.82 | 8.03 | 29.82 | 20.33 | -22.26 | -- | -- |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Achilles Therapeutics PLC ADR (ACHL)
| 27.97 | -1.22 | -82.04 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered... bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. Address: 245 Hammersmith Road, London, United Kingdom, W6 8PW Read more
CEO & Director
Dr. Iraj Ali Ph.D.
CEO & Director
Dr. Iraj Ali Ph.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Achilles Therapeutics PLC ADR (ACHL) stood at $ 141 Mln as on 30-Sep-24
The share price of Achilles Therapeutics PLC ADR (ACHL) is $1.48 (NASDAQ) as of 26-Mar-2025 09:30 EDT. Achilles Therapeutics PLC ADR (ACHL) has given a return of -22.26% in the last 3 years.
Achilles Therapeutics PLC ADR (ACHL) has a market capitalisation of $ 63 Mln as on 26-Mar-2025. As per Value Research classification, it is a company.
The P/B ratio of Achilles Therapeutics PLC ADR (ACHL) is 0.61 times as on 26-Mar-2025, a 72% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of Achilles Therapeutics PLC ADR (ACHL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Achilles Therapeutics PLC ADR (ACHL) and enter the required number of quantities and click on buy to purchase the shares of Achilles Therapeutics PLC ADR (ACHL).
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. Address: 245 Hammersmith Road, London, United Kingdom, W6 8PW
The CEO & director of Dr. Iraj Ali Ph.D.. is Achilles Therapeutics PLC ADR (ACHL), and CFO & Sr. VP is Dr. Iraj Ali Ph.D..
There is no promoter pledging in Achilles Therapeutics PLC ADR (ACHL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Achilles Therapeutics PLC ADR (ACHL) | Ratios |
|---|---|
|
Return on equity(%)
|
-57.28
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Achilles Therapeutics PLC ADR (ACHL) was $0 Mln.
